On this page

Benzonatate

Prescription ANDA TE AA Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Benzonatate
Generic name
Benzonatate
Dosage form
Capsule, Liquid Filled
Route
Oral
Marketing category
ANDA · ANDA
Labeler
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
13
Packages
24
Data completeness
83% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Benzonatate 100 mg/1 197397 View
Benzonatate 200 mg/1 197397 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Capsule, Liquid Filled
Route of administration
Oral
Presentations
37

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Decreased Tracheobronchial Stretch Receptor Activity [PE] PE 4 members — no class page
Non-narcotic Antitussive [EPC] EPC 4 members — no class page

Regulatory status

Source: Drugs@FDANDC Directory
Application number
040682
Application type
ANDA · Abbreviated New Drug Application
Approval date
July 30, 2007
Sponsor
HERITAGE PHARMS LABS
Products on application
2
Submissions recorded
4
Products approved under application 040682.
Product Trade name Form Strength Ingredient Status TE Flags
040682-001 BENZONATATE CAPSULE BENZONATATE Prescription AA
040682-002 BENZONATATE CAPSULE BENZONATATE Prescription AA

Therapeutic equivalence

Source: Orange Book
TE code
AA
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 040682.
Type No. Action Status Date Review
Supplement 11 Labeling Approved March 21, 2023 Standard
Supplement 4 Labeling Approved March 1, 2011 —
Supplement 3 Manufacturing (CMC) Approved April 6, 2010 —
Original application 1 Approved July 30, 2007 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260323). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260323 HUMAN PRESCRIPTION DRUG · 20251227 HUMAN PRESCRIPTION DRUG · 20241023

Boxed Warning

openFDA Drug Labeling

BOXED WARNING Hypersensitivity Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures. Psychiatric Effects Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking benzonatate in combination with other prescribed drugs. Accidental Ingestion and Death in Children Keep benzonatate out of reach of children. Accidental ingestion of benzonatate resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15 to 20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE ).

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Benzonatate capsules are indicated for the symptomatic relief of cough.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate Capsules should be swallowed whole. Benzonatate Capsules are not to be broken, chewed, dissolved, cut or crushed.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Hypersensitivity to benzonatate or related compounds.

WARNINGS Hypersensitivity Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures. Psychiatric Effects Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking benzonatate capsules in combination with other prescribed drugs. Accidental Ingestion and Death in Children Keep benzonatate capsules out of reach of children. Accidental ingestion of benzonatate capsules resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15 to 20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE ).

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Potential Adverse Reactions to benzonatate may include: Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule. CNS: sedation; headache; dizziness; mental confusion; visual hallucinations. GI: constipation; nausea; GI upset. Dermatologic: pruritus; skin eruptions. Other: nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity. Deliberate or accidental overdose has resulted in death, particularly in children. To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7. Benzonatate Capsules, USP contain 100 mg or 200 mg of benzonatate, USP. Benzonatate Capsules also contain: D&C Yellow No. 10, gelatin, glycerin, methylparaben sodium and propylparaben sodium. The white imprinting ink contains the following inactive ingredients: ammonium hydroxide, isopropyl alcohol, n-butyl alcohol, propylene glycol, shellac glaze, simethicone and titanium dioxide. FDA approved dissolution test specifications differ from USP. structure

OVERDOSAGE Intentional and unintentional overdose may result in death, particularly in children. The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion. Signs and Symptoms The signs and symptoms of overdose of benzonatate have been reported within 15 to 20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise. CNS stimulation may cause restlessness and tremors which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion. Treatment In case of overdose, seek seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage. Do not use CNS stimulants.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Benzonatate Capsules, USP are available as: 100 mg Oval Shape, imprint “100” with white ink, transparent yellow soft gelatin capsule NDC 23155-898-01 Bottles of 100 NDC 23155-898-05 Bottles of 500 200 mg Oblong Shape, imprint “200” with white ink, transparent yellow soft gelatin capsules NDC 23155-899-01 Bottles of 100 NDC 23155-899-05 Bottles of 500 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant container as defined in the USP. Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816 1.866.901.DRUG (3784) 51U000000461US01 Revised: 04/2024 image description

Adverse event reports

Source: openFDA FAERS
16,446
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: BENZONATATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II December 31, 2014 Zydus Pharmaceuticals USA Inc Failed Tablet/Capsule Specifications: Recall due to wet and/or leaking capsules. Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
65162-536-10 65162-536 Amneal Pharmaceuticals LLC 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (65162-536-10) June 4, 2010
65162-536-50 65162-536 Amneal Pharmaceuticals LLC 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (65162-536-50) June 4, 2010
65162-537-10 65162-537 Amneal Pharmaceuticals LLC 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (65162-537-10) June 4, 2010
65162-537-50 65162-537 Amneal Pharmaceuticals LLC 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (65162-537-50) June 4, 2010
71335-3169-1 71335-3169 Bryant Ranch Prepack 21 CAPSULE, LIQUID FILLED in 1 BOTTLE (71335-3169-1) August 11, 2026
71335-3169-2 71335-3169 Bryant Ranch Prepack 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (71335-3169-2) August 11, 2026
71335-3169-3 71335-3169 Bryant Ranch Prepack 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (71335-3169-3) August 11, 2026
71335-3169-4 71335-3169 Bryant Ranch Prepack 10 CAPSULE, LIQUID FILLED in 1 BOTTLE (71335-3169-4) August 11, 2026
23155-898-01 23155-898 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (23155-898-01) September 29, 2024
23155-898-05 23155-898 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (23155-898-05) September 29, 2024
23155-899-01 23155-899 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (23155-899-01) September 29, 2024
23155-899-05 23155-899 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (23155-899-05) September 29, 2024
0904-6564-60 0904-6564 Major Pharmaceuticals 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (0904-6564-60) September 4, 2007
10888-8125-1 10888-8125 Patheon Softgels Inc. 40000 CAPSULE, LIQUID FILLED in 1 BOX (10888-8125-1) December 6, 2010
10888-8126-1 10888-8126 Patheon Softgels Inc. 25000 CAPSULE, LIQUID FILLED in 1 BOX (10888-8126-1) October 6, 2010
63187-076-14 63187-076 Proficient Rx LP 14 CAPSULE, LIQUID FILLED in 1 BOTTLE (63187-076-14) November 1, 2018
63187-076-20 63187-076 Proficient Rx LP 20 CAPSULE, LIQUID FILLED in 1 BOTTLE (63187-076-20) November 1, 2018
63187-076-30 63187-076 Proficient Rx LP 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (63187-076-30) November 1, 2018
63187-076-40 63187-076 Proficient Rx LP 40 CAPSULE, LIQUID FILLED in 1 BOTTLE (63187-076-40) November 1, 2018
67296-2202-3 67296-2202 Redpharm Drug 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (67296-2202-3) September 29, 2024
67296-2207-1 67296-2207 Redpharm Drug 15 CAPSULE, LIQUID FILLED in 1 BOTTLE (67296-2207-1) September 29, 2024
68382-091-01 68382-091 Zydus Pharmaceuticals USA Inc. 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (68382-091-01) April 9, 2007
68382-247-01 68382-247 Zydus Pharmaceuticals USA Inc. 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (68382-247-01) April 9, 2007
68382-247-05 68382-247 Zydus Pharmaceuticals USA Inc. 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (68382-247-05) April 9, 2007
65162-536 65162-536 Amneal Pharmaceuticals LLC — June 4, 2010
65162-537 65162-537 Amneal Pharmaceuticals LLC — June 4, 2010
71335-3169 71335-3169 Bryant Ranch Prepack — September 29, 2024
23155-898 23155-898 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. — September 29, 2024
23155-899 23155-899 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. — September 29, 2024
0904-6564 0904-6564 Major Pharmaceuticals — September 4, 2007
10888-8125 10888-8125 Patheon Softgels Inc. — January 29, 1993
10888-8126 10888-8126 Patheon Softgels Inc. — October 30, 2007
63187-076 63187-076 Proficient Rx LP — June 4, 2010
67296-2202 67296-2202 Redpharm Drug — September 29, 2024
67296-2207 67296-2207 Redpharm Drug — September 29, 2024
68382-091 68382-091 Zydus Pharmaceuticals USA Inc. — April 9, 2007
68382-247 68382-247 Zydus Pharmaceuticals USA Inc. — April 9, 2007

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 13 sections on this page.